Oric Q1 FY26 net loss widens to $35.77 million; R&D expenses rise to $31.44 million

• Oric Pharmaceuticals posted a Q1 net loss of $35.77 million, widening from $30.02 million a year earlier, while loss per share narrowed to $0.34 from $0.42.
• Operating loss widened to $39.62 million as R&D expenses climbed to $31.4 million from $24.6 million; G&A held roughly flat at $8.2 million.
• Cash, cash equivalents and investments totaled $419.7 million, including $59.9 million of net proceeds raised under its ATM program, with runway expected into 2H 2028.
• Selected rinzimetostat 400 mg once daily as recommended Phase 3 dose with darolutamide, targeting initiation of Himalayas-1 Phase 3 registrational trial in post-abiraterone mCRPC in 1H 2026.
• Completed enrollment in enozertinib Phase 1b monotherapy in first-line EGFR exon 20 insertion NSCLC, with several enozertinib clinical updates expected in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605041605PRIMZONEFULLFEED9712662) on May 04, 2026, and is solely responsible for the information contained therein.